Beta Bionics (NASDAQ:BBNX) Research Coverage Started at William Blair

William Blair began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report published on Friday, MarketBeat reports. The brokerage issued a market perform rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Truist Financial raised their price target on Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Bank of America lowered their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. The Goldman Sachs Group boosted their price target on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, UBS Group began coverage on Beta Bionics in a research note on Tuesday, July 28th. They set a “buy” rating and a $22.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics Stock Performance

BBNX stock opened at $19.05 on Friday. The company has a market capitalization of $857.06 million, a P/E ratio of -11.55 and a beta of 3.13. Beta Bionics has a twelve month low of $8.80 and a twelve month high of $32.71. The business has a 50 day simple moving average of $16.14 and a 200-day simple moving average of $13.25.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million for the quarter. Research analysts predict that Beta Bionics will post -2.1 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Steven Jon Russell sold 4,222 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $53,239.42. Following the completion of the transaction, the insider directly owned 173,849 shares of the company’s stock, valued at approximately $2,192,235.89. This represents a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 4,896 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88. Following the sale, the chief financial officer owned 165,931 shares in the company, valued at $2,825,804.93. The trade was a 2.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 36,355 shares of company stock worth $512,943 in the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BBNX. Charles Schwab Investment Management Inc. increased its position in Beta Bionics by 0.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after purchasing an additional 931 shares during the last quarter. Deutsche Bank AG increased its stake in Beta Bionics by 3.4% during the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock worth $1,197,000 after acquiring an additional 1,296 shares during the last quarter. Summit Securities Group LLC acquired a new stake in Beta Bionics during the fourth quarter worth about $52,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after purchasing an additional 1,818 shares during the period. Finally, Verition Fund Management LLC raised its holdings in shares of Beta Bionics by 4.0% in the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock worth $940,000 after purchasing an additional 1,823 shares during the period.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.